Mechanisms of kinetic stabilization by the drugs paclitaxel and vinblastine

Brian T Castle1, Seth McCubbin2, Louis S Prahl1

  • 1Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455.

Insights

Microtubule-targeting agents (MTAs) stabilize microtubules through two distinct mechanisms. This research clarifies how MTAs like paclitaxel and vinblastine affect microtubule dynamics, crucial for cancer drug development.

Area of Science:

  • Cell Biology
  • Biochemistry
  • Pharmacology

Background:

  • Microtubule-targeting agents (MTAs) are vital chemotherapeutics and biological probes.
  • MTAs function by binding tubulin and kinetically stabilizing microtubules, inhibiting dynamic instability.
  • The precise molecular mechanisms and thermodynamic/kinetic underpinnings of MTA-induced kinetic stabilization remain incompletely understood.

Purpose of the Study:

  • To elucidate the kinetic and thermodynamic basis of kinetic stabilization induced by paclitaxel and vinblastine.
  • To differentiate the mechanisms of kinetic stabilization employed by assembly-promoting (paclitaxel) and disassembly-promoting (vinblastine) MTAs.
  • To define the fundamental requirements for microtubule dynamic instability and its suppression by MTAs.

Main Methods:

  • Integration of a computational model for microtubule assembly.
  • Application of nanometer-scale fluorescence microscopy in live cells.
  • Analysis of kinetic and thermodynamic parameters governing tubulin dynamics.

Main Results:

  • Identified two distinct modes of kinetic stabilization by MTAs in live cells.
  • Vinblastine exhibits true kinetic stabilization by suppressing on-off kinetics.
  • Paclitaxel demonstrates "pseudo" kinetic stabilization by reducing the GTP- and GDP-tubulin energy difference.
  • Both MTAs effectively stabilize microtubules against disassembly, particularly without a GTP cap.

Conclusions:

  • The study clarifies the distinct molecular mechanisms underlying kinetic stabilization by different classes of MTAs.
  • Understanding these mechanisms provides insight into microtubule dynamics and MTA efficacy.
  • Findings contribute to the rational design of novel chemotherapeutic agents targeting microtubule dynamics.

Related Concept Videos

Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.3K